1-(4-苄基氧基苯基)-5-甲基-2(1H)-吡啶酮 | 1076199-02-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4-苄基氧基苯基)-5-甲基-2(1H)-吡啶酮
• 英文名称: 1-(4-benzyloxyphenyl)-5-methyl-1H-pyridin-2-one
• 英文别名: 1-(4-Benzyloxyphenyl)-5-methyl-2(1H)-pyridone；5-methyl-1-(4-phenylmethoxyphenyl)pyridin-2-one
• CAS: 1076199-02-4
• 化学式: C₁₉H₁₇NO₂
• 分子量: 291.349
• InChiKey: AIZOFIUTSSIOBR-UHFFFAOYSA-N

物化性质

• 沸点：
  487.1±37.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-苄基氧基苯基)-5-甲基-2(1H)-吡啶酮 在 5%-palladium/activated carbon 、 氢气 、 potassium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 144.0h， 生成 5-methyl-1-[4-(4-piperidin-1-ylbutoxy)phenyl]-1H-pyridin-2-one
  参考文献：
  名称：

  Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents

  摘要：

  A total of 24 pirfenidone derivatives were designed, synthesized and evaluated for their inhibitory activity against the human lung fibroblast cell line MRC-5. These compounds showed the remarkable proliferation inhibition against MRC-5 compared to pirfenidone as the positive control. The possible mechanism of this kind of derivatives as antifibrotic agents was explored. The molecular docking and p38 binding affinity assays demonstrated that the antifibrotic potential of the pirfenidone derivatives was possibly through the inhibition of p38 MAPK signaling pathway. The data from this study suggested that p38 might be a potential therapeutic target for the new generation antifibrotics. All the pirfenidone derivatives are reported here for the first time. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.038
• 作为产物：
  描述：

  4-苄氧基溴苯 、 2-羟基-5-甲基嘧啶 在 copper(l) iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-苄基氧基苯基)-5-甲基-2(1H)-吡啶酮
  参考文献：
  名称：

  SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION

  摘要：

  本公开涉及吡非尼酮（5-甲基-1-苯基-2-(1H)-吡啶酮）及其衍生物和其药用盐，这些化合物的用途作为药物，并用于制造用于治疗或延缓肺动脉高压的药物。

  公开号：

  US20170290819A1

文献信息

• COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS
  申请人：Kossen Karl

  公开号：US20090318455A1

  公开（公告）日：2009-12-24

  Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

  公开了用于治疗炎症和纤维化疾病的化合物和方法，包括用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物对p38 MAPK的抑制效力较低；并且其中接触是在SAPK调节浓度下进行的，该浓度对化合物抑制p38 MAPK的抑制浓度百分比较低。还公开了吡非尼酮的衍生物和类似物，它们可用于调节应激活化蛋白激酶（SAPK）系统。
• Small molecule therapies for pulmonary hypertension
  申请人：Creighton University

  公开号：US10420759B2

  公开（公告）日：2019-09-24

  The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.

  本公开涉及吡非尼酮（5-甲基-1-苯基-2-(1H)-吡啶酮）及其衍生物和其药学上可接受的盐、这些化合物作为药物的用途，以及用于制造治疗或延缓肺动脉高压发病或发展的药物。
• METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS
  申请人：Olgin Jeff

  公开号：US20100190731A1

  公开（公告）日：2010-07-29

  The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.
• Methods for Treating Acute Myocardial Infarctions and Associated Disorders
  申请人：Olgin Jeff

  公开号：US20110218515A1

  公开（公告）日：2011-09-08

  The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.
• METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS
  申请人：Kossen Karl

  公开号：US20120014917A1

  公开（公告）日：2012-01-19

  The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.